Mark Schoenberg Sells 5,222 Shares of Urogen Pharma (NASDAQ:URGN) Stock

by · The Cerbat Gem

Urogen Pharma (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 5,222 shares of the business’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60. Following the sale, the insider owned 139,763 shares in the company, valued at $3,815,529.90. The trade was a 3.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Urogen Pharma Stock Up 1.2%

Shares of Urogen Pharma stock traded up $0.33 on Tuesday, hitting $27.58. The company’s stock had a trading volume of 434,080 shares, compared to its average volume of 799,607. Urogen Pharma has a 52-week low of $6.73 and a 52-week high of $32.37. The firm has a fifty day moving average price of $24.84 and a 200-day moving average price of $22.75. The company has a market capitalization of $1.34 billion, a P/E ratio of -10.03 and a beta of 1.59.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to analysts’ expectations of $44.83 million. As a group, analysts expect that Urogen Pharma will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

URGN has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Urogen Pharma in a research report on Wednesday, June 3rd. LADENBURG THALM/SH SH initiated coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $33.00 price objective on shares of Urogen Pharma in a research report on Tuesday, March 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.67.

Get Our Latest Report on URGN

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. increased its stake in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after purchasing an additional 486 shares in the last quarter. State of Wyoming acquired a new stake in Urogen Pharma during the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. increased its position in Urogen Pharma by 1,594.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

About Urogen Pharma

(Get Free Report)

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

Recommended Stories